Callan Family Office, LLC Rapt Therapeutics, Inc. Transaction History
Callan Family Office, LLC
- $1.57 Trillion
- Q4 2024
A detailed history of Callan Family Office, LLC transactions in Rapt Therapeutics, Inc. stock. As of the latest transaction made, Callan Family Office, LLC holds 58,040 shares of RAPT stock, worth $67,326. This represents 0.01% of its overall portfolio holdings.
Number of Shares
58,040Holding current value
$67,326% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding RAPT
# of Institutions
102Shares Held
49.1MCall Options Held
26.7KPut Options Held
2.4K-
Medicxi Ventures Management (Jersey) LTD22.4MShares$25.9 Million7.76% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.94MShares$3.41 Million0.0% of portfolio
-
Column Group LLC San Francisco, CA2.68MShares$3.11 Million7.75% of portfolio
-
Black Rock Inc. New York, NY2.44MShares$2.83 Million0.0% of portfolio
-
Kingdon Capital Management, L.L.C. New York, NY1.73MShares$2 Million0.42% of portfolio
About RAPT Therapeutics, Inc.
- Ticker RAPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,656,600
- Market Cap $34.4M
- Description
- RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...